NCT06857305 2025-03-04Efficacy and Safety of Biweekly Regimen of Eribulin Versus a Standard Regimen for the Treatment of Locally Recurrent or Metastatic HER2-negative Breast Cancer: a Multicenter, Randomized, Open-label, Phase III TrialCancer Institute and Hospital, Chinese Academy of Medical SciencesPhase 3 Enrolling by invitation192 enrolled